Recently, the mechanisms of resistance toward combined BRAF and MEK inhibitors in MM have also been associated with the emergence of a transient population of tumor cells that display NSCS properties, confirming the importance of non-genetic drivers of drug tolerance in these tumors47. The gene discussed is BRAF; the disease is Miyoshi myopathy.